Physician Sentiment on NUBEQA®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-14. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT04736199

What do oncologists think of the ARANOTE trial (NUBEQA®)?

ARANOTE — Metastatic castration-sensitive (hormone-sensitive) prostate cancer — darolutamide + ADT, without docetaxel (chemotherapy-free doublet)

FDA APPROVED · Jun 2025FDA-approved June 3, 2025, for metastatic castration-sensitive prostate cancer (mCSPC) — darolutamide plus androgen deprivation therapy, expanding the mCSPC indication to treatment with or without docetaxel (the prior August 2022 ARASENS approval covered the combination with docetaxel).

Physicians are genuinely mixed on ARANOTE: 13% of 8 verified physician voices positive, 25% nuanced (praising the result while flagging a caveat), 50% neutral, 12% critical.

13%

25%

50%

12%

Positive 13% Nuanced 25% Neutral 50% Critical 12%

Denominator: 8 distinct verified physician voices across 14 oncologist posts, 2024-12-28 to 2025-06-08. Sponsor: Bayer (with Orion Pharma)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT04736199 · FDA — ARANOTE mCSPC approval (Jun 2025)

FDA approval (Jun 3, 2025): darolutamide with androgen deprivation therapy for metastatic castration-sensitive prostate cancer — expanding the indication to treatment with or without docetaxel (based on ARANOTE, NCT04736199).

Physician voices — verbatim

Representative positive voice

Congrats Alicia @CaPsurvivorship for oral ab#5004 @ASCO #ASCO25 👉https://t.co/rsGcdqfN31👉HRQoL data from ph3 ARANOTE trial #prostatecancer 👉Darolutamide improved overall well-being, pain & symptoms vs placebo 👇 #FredSaad @OncoAlert @urotoday @PCF_Science

Neeraj Agarwal, MD, FASCO

@neerajaiims

Representative nuanced voice

Just in time as Darolutamide is now also @US_FDA approved for mHSPC based off ARANOTE study - Ph III, metastatic (by bone scan or CT/MRI) hormone-sensitive prostate cancer. - rPFS NR (statistically significant) but OS (not statistically significant) #OncTwitter #MedTwitter https://t.co/yL2yY9h78u

Oncology Brothers

@OncBrothers

Representative critical voice

Using patients from LMICs without subsequent access, solely to get the drug approved in HICs, is unethical.

Bishal Gyawali, MD, PhD, FASCO

@oncology_bg

Full physician voice list (8)

Physician	Comment (verbatim)	Sentiment	Impressions
Toni Choueiri, MD @DrChoueiri	And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ES…	Neutral	42,936
Michael Serzan, MD @MikeSerzanMD	🗣️Prostate Oral Abstract #ASCO25 👉Abst5004: Dr @CaPsurvivorship presenting #HRQoL w/ darolutamide on #ARANOTE 📈HRQoL assessed by: - FACT-P: Funct Assessmt of Cancer Therapy–Prostate - BPI-SF: Brief Pain Inventory–Short Form	Neutral	6,633
Oncology Brothers @OncBrothers	Just in time as Darolutamide is now also @US_FDA approved for mHSPC based off ARANOTE study - Ph III, metastatic (by bone scan or CT/MRI) hormone-sensitive prostate cancer. - rPFS NR (statistically significant) but OS (not statistically s…	Nuanced	5,904
Neeraj Agarwal, MD, FASCO @neerajaiims	Congrats Alicia @CaPsurvivorship for oral ab#5004 @ASCO #ASCO25 👉https://t.co/rsGcdqfN31👉HRQoL data from ph3 ARANOTE trial #prostatecancer 👉Darolutamide improved overall well-being, pain & symptoms vs placebo 👇 #FredSaad @OncoAlert @urotoda…	Positive	2,748
Yakup Ergün @dr_yakupergun	Every time I come across the ARANOTE study, I want to shout the same thing. This image makes it even clearer: abiraterone, enzalutamide, and apalutamide were already approved for mCSPC back in 2019. The ARANOTE trial was initiated well afte…	Neutral	2,369
Martin Schoen MD MPH @mwschoen	ARANOTE used inferior control that was acceptable in 2013 with LATITUDE, not in 2021. However, ethics of trials in low income countries to approve drugs that create competition in high income countries is complex. Daro is effective in mHSPC…	Nuanced	121
Bishal Gyawali, MD, PhD, FASCO @oncology_bg	Using patients from LMICs without subsequent access, solely to get the drug approved in HICs, is unethical.	Negative	119
Dr Amol Akhade @SuyogCancer	Do most ethics committee in LMICs understand the such intricacies? Do those members know and look into such details ? My answer is unfortunate NO. Most of them see if pt is not getting harm , financially and physical side effects . They do…	Neutral	9

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Regulatory

NUBEQA® — FDA status

FDA APPROVEDNUBEQA® (darolutamide) is FDA-approved for prostate cancer — non-metastatic castration-resistant disease (nmCRPC) and metastatic castration-sensitive disease (mCSPC), the latter with or without docetaxel. For the full, current list of FDA indications and prescribing information, see nubeqa.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

NUBEQA® sentiment — FAQ

ARANOTE

What do oncologists think of the ARANOTE trial (NUBEQA®)?

Across 8 verified physician voices in KOL Pulse's index for ARANOTE, 13% expressed positive sentiment, 25% were nuanced (praising the result while flagging a caveat), 50% were neutral, and 12% were critical. Positive voices highlight the radiographic-progression-free-survival benefit of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, with a favorable, low-toxicity safety profile and improved health-related quality of life — a chemotherapy-free doublet option; nuanced and critical voices flag the ADT-alone control arm chosen after androgen-receptor-inhibitor doublets were already standard of care, overall-survival immaturity, and the ethics of conducting the trial largely in lower-income countries.

Where can I find the ARANOTE trial data for NUBEQA® (darolutamide)?

ARANOTE is registered as NCT04736199 and studied NUBEQA® (darolutamide) in Metastatic castration-sensitive (hormone-sensitive) prostate cancer — darolutamide + ADT, without docetaxel (chemotherapy-free doublet). KOL Pulse's ARANOTE trial profile is coming soon.

Regulatory

Is NUBEQA® (darolutamide) FDA approved?

NUBEQA® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.